Introduction {#sec1}
============

Deoxyglycosides are an important class of carbohydrates commonly found in nature as part of biologically active glycoconjugates.^[@ref1]^ These compounds are characterized by the lack of substitution at one or several positions around the carbohydrate ring, often at C-2, which makes them more challenging to synthesized than their fully oxygenated counterparts. The absence of directing groups adjacent to the anomeric center to bias the nucleophile approach during the glycosylation reaction, often leads to mixtures of anomers and/or Ferrier-type products.^[@ref2]^ Owing to their relevance in drug discovery, research efforts have focused in achieving their stereoselective synthesis.^[@ref3]^

Coupling reactions involving glycals are one of the most atom-efficient routes to access deoxyglycosides.^[@ref4]^ Traditional methods to yield the corresponding 2-deoxyglycoside rely on acid catalyzed direct addition of an alcohol to the glycal, which often leads to either moderate to low yields and/or variable selectivities which are dependent on the nature of the OH nucleophile (e.g., primary vs secondary, axial vs equatorial) with 2,3-unsaturated glycosides and hydrolyzed starting material as common side products.^[@cit2a],[@cit3a],[@cit3q]^ However, most acid-catalyzed processes to access 2,3-unsaturated glycosides directly, which are also versatile synthons in organic chemistry,^[@ref5]^ tend to use harsh promoters, required specific protected building blocks, and often lead to moderate overall yields and diastereocontrol, which has limited their utility.^[@cit3a]^ Given the range of glycoside donor and OH nucleophile reactivity profiles, there is currently no universal Lewis acid glycosylation promoter that can be used for the activation of glycals.^[@ref3]^ Thus, there is a need to find improved and more general catalysts to access these high value glycosides.

Our group has been interested over the past few years in the development of practical, selective and catalytic methods for the direct activation of glycals using thiourea-based organocatalysts,^[@cit4b]−[@cit4d]^ as well as palladium and gold catalytic activators.^[@ref9]^ Encouraged by our previous work, we undertook synthetic studies toward the development of a metal-free and improved organocatalytic method for the activation of glycals.

Trivalent boron reagents are often employed as Lewis acids because of their ubiquitous electrophilic nature and ability to reversibly form bonds with oxygen and thus are attractive catalysts in glycosylation chemistry including examples in regioselective glycosylations.^[@cit3a],[@cit3p],[@ref6]^ Among the boron-based Lewis acids available, B(C~6~F~5~)~3~ (BCF) has demonstrated extensive versatility in a wide variety of reactions including borylation, hydrogenation, hydrosilylation, frustrated Lewis pair (FLP) chemistry, and Lewis acid catalysis.^[@ref7]^ In the context of glycosylation chemistry, the utility of BCF has only been shown in the activation of fully substituted trichloroacetimidate glycosyl donors in good to excellent yields and moderate to good diastereoselectivity,^[@ref8]^ with no examples reported in the synthesis of deoxyglycosides.

Herein we describe the metal-free, atom-economic, and versatile substrate-controlled borane-catalyzed highly α-stereoselective synthesis of deoxyglycosides directly from glycals ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![BCF-Catalysed Synthesis of 2,3-Unsaturated Glycosides from "Disarmed" Glycals (Pathway A) and 2-α-Deoxyglycosides from "armed" Glycals (Pathway B)](jo-2018-02613u_0001){#sch1}

Results and Discussion {#sec2}
======================

Initial studies began by screening BCF for its ability to promote the stereoselective glycosylation of peracetylated galactal **1a** with glucoside acceptor **2a** in the presence of different catalyst loadings, solvents, and temperatures. It was found that 5 mol % BCF in toluene at 75 °C was the optimum condition to yield the corresponding 2,3-unsaturated glycoside **3a** after 2 h (88%, α:β 30:1, entry 1 in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Reactions were less efficient at lower catalyst loadings or at lower temperatures; changing the solvent to CH~2~Cl~2~ or CH~3~CN was also detrimental to the reaction (see [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf) in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf) ([SI](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf)) for solvent and temperature screen details). Having established the optimal reaction conditions, our attention then turned to exploring the substrate scope of the reaction between **1a** and a range of OH nucleophiles **2b**--**2k** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). In all cases, reactions proceeded smoothly within 1.5--4 h and in good to excellent yields and a clear preference for the α-products, demonstrating the reaction is tolerant of primary, secondary, and phenolic OH nucleophiles, as well as common alcohol protecting groups (e.g., acetals, ethers, and esters).

###### Glycosylation Reactions with Galactal **1a**[c](#t1fn3){ref-type="table-fn"}

![](jo-2018-02613u_0006){#GRAPHIC-d7e281-autogenerated}

![](jo-2018-02613u_0007){#gr6}

Isolated yield.

Determined by ^1^H-NMR.

Reaction did not proceed in the absence of catalyst.

Activation with BF~3~.OEt~2~ afforded **3a** in 19% as a 6:1 mixture of anomers.

Glycosylations with primary alcohols **2b**--**2e** afforded the corresponding 2,3-unsaturated glycosides in 72--86% yield within 2 h and with a 30:1 α:β ratio (entries 2--5). Reactions with secondary alcohols such as 4-methoxyphenol **2i**, cholesterol **2j**, or *N*-hydroxysuccinimide **2k** (entries 9--11) proceeded smoothly giving the desired products in similar high α-selectivity (\>30:1 to \>20:1, α/β ratio) and yields of 77--82%. Reactions with glycosides **2g**, **2h**, and propargyl alcohol **2f** (entries 6--8) prove to be more challenging and afforded the products in lower yields and stereoselectivity, albeit in favor of the α-products (67--86%, 6:1--7:1 α:β ratio). The ability to effectively activate galactals is noteworthy, as generally glycal substrates that favor a bigger shift toward ^5^*H*~4~ conformations (e.g., glucals) undergo rearrangement more readily than their C-4 epimer galactals where the equilibria is shifted toward the ^4^*H*~5~ form and as a result galactals often give mixtures of products, as well as lower overall yields.^[@ref10]^

The scope of the reaction was further investigated with regards to glycal donor. To this end, a series of peracetylated glycals: [d]{.smallcaps}-glucal **1b**, [l]{.smallcaps}-fucal **1c**, [d]{.smallcaps}-xylal **1d** and [l]{.smallcaps}-rhamnal **1e** were subjected to the reaction conditions with **2e** as the model OH nucleophile ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). In general, moderate to good yields (65--86%) and α-selectivities were obtained in all cases leading to the formation of 2-deoxy and 2,6-dideoxy Ferrier-type products. Best diastereoselectivities were observed for 2,6-dideoxyglycals (15:1--30:1 α:β, **1c**-**1e**), while glucal **1b** yielded **4b** in 86% yield and a 3:1 α:β ratio.

![Reaction of Glycals **1a**--**1e**, with Glycosyide Acceptors **2e**](jo-2018-02613u_0002){#sch2}

![Synthesis of Rare Glycosides **6--8**](jo-2018-02613u_0003){#sch3}

The synthetic utility of our strategy was further exemplified on the preparation of rare glycoside analogues **6**--**8**, which are often difficult to access by traditional methods^[@ref11]^ bearing a Boc-protected amino propyl linker that could be used for array conjugation ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). Glycosylation of 3-(Boc-amino)-1-propanol with **1c**, followed by ester deprotection gave 2,3-unsaturated fucoside **5** in 83% yield (2 steps) and a 10:1 α/β ratio. Alkene reduction of **5** with Rh--Al~2~O~3~ afforded α-[l]{.smallcaps}-Rhodinose **6** in 76% yield. Alternatively, subjecting **5** to reduction followed by treatment with Dess-Martin periodinane gave α-[l]{.smallcaps}-cinerulose **7** (55%), while direct alcohol oxidation of **5** yields α-[l]{.smallcaps}-aculose **8** (79%).

Next, we explored whether "armed" glycosides lacking a leaving group at C-3 could undergo BCF-activation and give substitution products selectively. To probe this, reactions between perbenzylated galactal **9a**, acceptor **2a** and BCF were screened at different catalyst loadings, solvents and temperatures as before. Best results were found when 5 mol % B(C~6~F~5~)~3~ was used in toluene at 50 °C to give 2-deoxyglycoside **10a** after 2 h (88%, α/β \> 30:1, entry 1, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). As before, reactions were less efficient at lower catalyst loadings or temperatures below 50 °C and changing the solvent to CH~2~Cl~2~, CH~3~CN or CF~3~Ph was also detrimental ([SI Table S2](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf) for full details).

###### Reaction of Glycals **9a**--**d** and **11a**--**c** with Model Glycosyide Acceptors **2a**, **2e**, or **2g**

![](jo-2018-02613u_0008){#GRAPHIC-d7e559-autogenerated}

  entry   R^1^      R^2^                    R^3^   product   time (h)                                  yield (%)[a](#t2fn1){ref-type="table-fn"}   α/β[b](#t2fn2){ref-type="table-fn"}                                     
  ------- --------- ----------------------- ------ --------- ----------------------------------------- ------------------------------------------- ----------------------------------------------------------------------- ------
  1       **9a**    Bn                      Bn     Bn        **10a**                                   1                                           88[d](#t2fn4){ref-type="table-fn"}^,^[e](#t2fn5){ref-type="table-fn"}   21:1
  2       **9a**    Bn                      Bn     Bn        **10c**                                   1                                           94                                                                      26:1
  3       **9a**    Bn                      Bn     Bn        **10e**                                   2                                           84                                                                      30:1
  4       **9a**    Bn                      Bn     Bn        **10g**                                   7                                           62                                                                      25:1
  5       **9a**    Bn                      Bn     Bn        **10h**                                   7                                           68                                                                      20:1
  6       **9b**    TBS                     TBS    TBS       **11b**                                   1                                           92                                                                      30:1
  7       **9c**    MOM                     MOM    MOM       **11c**                                   1                                           71                                                                      20:1
  8       **9d**    Si(^*t*^Bu)~2~          MOM    **11d**   1                                         82                                          20:1                                                                    
  9       **11a**   Bn                      Bn     Bn        **12a**[c](#t2fn3){ref-type="table-fn"}   17                                          54                                                                      30:1
  10      **11b**   O\[Si(*i*-Pr)~2~\]~2~   Bn     **12b**   17                                        78                                          30:1                                                                    
  11      **11c**   O\[Si(*i*-Pr)~2~\]~2~   TIPS   **12c**   17                                        75                                          30:1                                                                    
  12      **11c**   O\[Si(*i*-Pr)~2~\]~2~   TIPS   **13**    17                                        86                                          30:1                                                                    
  13      **11c**   O\[Si(*i*-Pr)~2~\]~2~   TIPS   **14**    17                                        64                                          20:1                                                                    

Isolated yield.

Determined by ^1^H NMR.

10% Ferrier product **12a′** also isolated.

Reaction did not proceed in the absence of catalyst.

Reaction with BF~3~.OEt~2~ afforded **10a** (\<35%) and a mixture of products and starting material.

To explore the substrate scope of the glycosylation, galactals **9b**--**d** and glucals **11a**--**c** were reacted with a range of primary and secondary OH nucleophiles **2a**, **2e**, or **2g** under the optimized reaction conditions. In all cases, reactions proceeded smoothly in yields of 62--94% and high α-selectivity (20:1--30:1 α:β), with secondary OHs requiring longer reaction times (entries 4 and 5 vs 1--3). Subsequently, a series of differentially protected galactals **9b**--**d** and glucals **11a**--**c** bearing benzyl, methoxymethyl acetal, silyl ethers and acetals, and siloxane protecting groups were prepared and subjected to the reaction conditions to investigate the effect of glycal donor on the reaction. Pleasingly, reactions involving all galactals were complete within 1--7 h, in good yields (71--82%) and high α-selectivities (20:1 to 30:1 α/β) (entries 6--8). The reaction was also amenable to glycosylations with glucal substrates, albeit required longer reaction times (17 h) and afforded the glycoside products in moderate to good yields (54--86%) with similarly high α-stereocontrol. Siloxane protected donors **11b** and **11c** gave better yields that perbenzylated glucal **11a** (entries 9--13) as expected.^[@cit4c]^ These results further highlight that the catalytic system works well across a range of reactivity profiles in both the glycal moiety and nucleophile acceptor.

To probe the mechanism of this versatile reaction, deuterated perbenzylated galactal **15** was reacted with **2a** to yield α-glycoside **16a** and **16b** (90% yield) as a 2:1 mixture of cis/trans products, with a preference for syn addition of both H and O-nucleophile across the double bond ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}A). Addition of K~2~CO~3~ to the reaction between either **1a** or **9a** with **2a** inhibited the reaction, which supports an acid catalyzed process. Monitoring the reaction between **1a** or **9a** and hexafluoroisopropanol **17** ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}B) by ^1^H NMR over 60 min at 45 °C or 90 min at RT, respectively, only showed anomeric signals corresponding to the starting material and product, without any observable changes in the anomeric ratio of the product throughout the time scales of the reaction ([SI Figures S1 and S3](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf)).^[@ref13]^ Moreover, subjecting a 4:1 α/β-anomeric mixture of **10a** to the reaction conditions in the presence of acceptor **2a** gave no change in the anomeric ratio (see [SI](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf) for details). These results suggest the reaction proceeds via short-lived intermediates and that the high α-selectivity is not likely the result of anomerization. ^19^F-NMR of the reactions ([SI Figures S2 and S4](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf)) showed the appearance of fluorinated signals assigned to products **18** and **19**, respectively, and also shifts associated with the formation of other BCF species, suggesting the presence of BCF-adducts. Moreover, ^1^H NMR spectroscopy studies in Toluene-d^8^ of a 1:1 mixture of BCF with galactal donor **1a** or **9a**, also showed H-shifts associated with the enol ether alkene protons, in each case ([SI Figures S5 and S7](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf)). ^19^F-NMR of the same mixtures showed additional signals associated with several distinct BCF-species ([SI Figures S6 and S8](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf)), suggesting activation of the glycal enol ethers by BCF can take place and formation of adducts. Interestingly, ^1^H NMR equimolar mixtures of B(C~6~F~5~)~3~ and OH nucleophile **2a** at room temperature showed proton shifts associated with **2a** ([Figure S9](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf)). This effect was more evident in the ^19^F-NMR spectra of the same mixtures ([SI Figure S10](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf)) which showed the shift of the fluorine signals from the catalysts and appearance of different fluorinated species, further supporting the formation of an adduct between the catalyst and the OH nucleophile. This is in agreement to previous reports of glycosyl acceptor activation with boron-based catalysts such as BCF and PhBF~2~ in the acid--base activation of trichloroacetimidate glycosyl donors.^[@cit8b],[@ref12]^

![Model Glycosylations of **2a** or **17** with Glycal Donors **15**, **1a**, or **9a**](jo-2018-02613u_0004){#sch4}

As our preliminary findings suggest, BCF could act as a Lewis acid to promote the effective allylic rearrangement^[@ref13]^ (A) of deactivated glycals such as **1a** to form transient oxocarbenium ion (B) that can undergo nucleophilic substitution by the BCF-activated nucleophile adduct (H---BCF---OR) in a stereoselective manner to give 2,3-unsaturated glycosides. In the presence of more reactive glycals, which lack a leaving group at C-3 (e.g., **9a**), enol ether direct activation to form oxacarbenium ion (D) might take place, which after nucleophilic substitution by the BCF-activated nucleophile and concomitant protonolysis leads to deoxyglycoside products. In both instances, there is a clear preference for an α-face nucleophilic approach, likely due to sterics and a favorable anomeric effect^[@ref14]^ ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}, top). However, in the presence of Lewis basic oxygen atoms, BCF coordination to the pyran oxygen in the donor is also possible. Therefore, an acid--base catalyzed mechanism whereby the boron ate adduct promotes both oxocarbenium ion formation and nucleophile activation can not be discarded and it is likely to occur in parallel ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}, bottom). Further investigations are ongoing to better understand the mechanism of this reaction.

![Proposed Mechanism](jo-2018-02613u_0005){#sch5}

Conclusions {#sec3}
===========

In summary, we have described the unprecedented BCF-catalyzed substrate-controlled stereoselective synthesis of α-deoxyglycosides directly from glycals. We show that 2,3-unsaturated α-*O*-glycoside products are obtained with deactivated glycals at 75 °C, while 2-α-deoxyglycosides are formed with activated glycals lacking a leaving group at C-3 at slightly lower temperatures. This metal-free and versatile reaction is applicable to a range of glycal donors and nucleophile acceptors, and is tolerant of most common protecting groups. The reaction proceeds with good to excellent yields and high selectivity for the α-anomer. We exemplify the robustness and utility of the approach in the stereoselective synthesis of a series of oligosaccharides, glycosyl-amino acids, and other glyco-conjugates including rare glycosides analogues of α-[l]{.smallcaps}-Rhodinose α-[l]{.smallcaps}-cinerulose and α-[l]{.smallcaps}-aculose. Work from our lab is currently underway to exploit this chemistry for the stereoselective synthesis of other important glycosides.

Experimental Section {#sec4}
====================

General Experimental Procedures {#sec4.1}
-------------------------------

Chemicals were purchased and used without further purification. Glycal donors **1a**--**1e**, **9a**, and **11a** were purchased from Carbosynth and OH acceptors **2b**, **2e**, **2f**, **2h**, **2i**, **2j**, and **2k** were obtained from Sigma-Aldrich. Galactal donors **9b** and **9c** and glycosyl acceptors **2a**, **2c**, and **2d** were prepared following literature procedures,^[@cit4d]^ while glucal **11b** and **11c** and glycosyl acceptor **2g** were synthesized by Balmond et al. reported methods.^[@cit4c]^ Dry solvents were obtained by distillation using standard procedures or by passage through a column of anhydrous alumina using equipment from Anhydrous Engineering (University of Bristol) based on the Grubbs' design. Reactions requiring anhydrous conditions were performed under nitrogen; glassware and needles were either flame-dried immediately prior to use or placed in an oven (150 °C) for at least 2 h and allowed to cool either in a desiccator or under reduced pressure; liquid reagents, solutions, or solvents were added via syringe through rubber septa; solid reagents were added via Schlenk type adapters. Teflon rings were used between the joints of the condensers and round-bottom flasks. Reactions were monitored by TLC on Kieselgel 60 F254 (Merck). Detection was by examination under UV light (254 nm) and by charring with 10% sulfuric acid in ethanol. Flash column chromatography was performed using silica gel \[Merck, 230--400 mesh (40--63 μm)\]. Extracts were concentrated in vacuo using both a Büchi rotary evaporator (bath temperatures up to 40 °C) at a pressure of either 15 mmHg (diaphragm pump) or 0.1 mmHg (oil pump), as appropriate, and a high vacuum line at room temperature. ^1^H NMR and ^13^C NMR spectra were measured in the solvent stated at 400 or 500 MHz. Chemical shifts are quoted in parts per million from residual solvent peak (CDCl~3~: ^1^H--7.26 ppm and 13C--77.16 ppm) and coupling constants (J) given in Hertz. Multiplicities are abbreviated as b (broad), s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), or combinations thereof. Mass spectra were determined by the University of Bristol mass spectrometry service by electrospray ionization ([SI](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf)) modes. The units of the specific rotation, (deg·mL)/(g·dm), are implicit and are not included with the reported value. Concentration *c* is given in g/100 mL.

General Glycosylation Procedure {#sec4.2}
-------------------------------

Glycal donor (1.0 equiv), OH nucleophile acceptor (0.75 equiv), and B(C~6~F~5~)~3~ (5 mol %) were weighed into an oven-dried microwave vial, sealed and placed under vacuum for 1 h. Then the vial was filled with N~2~ followed by the addition of ∼1.0 mL of anhydrous toluene. The solutions were stirred and heated at 75 °C for Ferrier glycosylation and 50 °C for 2-deoxy glycosylation until the reaction was determined to be complete by either TLC or NMR analysis of the crude material (times are given in [Tables S1](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf) and [S2](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.8b02613/suppl_file/jo8b02613_si_001.pdf) and [Tables [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [2](#tbl2){ref-type="other"} of the main manuscript). The reaction mixture was concentrated in vacuo and the dried residue was purified by silica gel column chromatography.

### Methyl-6-*O*-(4,6-di-*O*-acetyl-2,3-dideoxy-α-[d]{.smallcaps}-*threo*-hex-2-enopyranosyl)-2,3,4-tri-*O-*benzyl-α-[d]{.smallcaps}-glucopyranoside **3a**) {#sec4.2.1}

Following the general glycosylation procedure, donor **1a** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.01 mmol), and acceptor **2a** (64 mg, 0.14 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 6:1 to 3:1) **3a** as a colorless oil (82 mg, 88%). Spectroscopic data in agreement with literature.^[@ref15]^

### Benzyl-4,6-di-*O*-acetyl-2,3-dideoxy-α-[d]{.smallcaps}-*threo*-hex-2-enopyranoside (**3b**) {#sec4.2.2}

Following the general glycosylation procedure, donor **1a** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.01 mmol) and acceptor **2b** (15 mg, 0.14 mmol) to afford following purification by column chromatography (Hexane:EtOAc, 12:1 to 8:1) **3b** as a colorless oil (37 mg, 84%). Spectroscopic data in agreement with literature.^[@ref15]^

### Methyl-6-*O*-(4,6-di-*O*-acetyl-2,3-dideoxy-α-[d]{.smallcaps}-*threo*-hex-2-enopyranosyl)-2,3,4-tri-*O-*benzoyl-α-[d]{.smallcaps}-glucopyranoside (**3c**) {#sec4.2.3}

Following the general glycosylation procedure, donor **1a** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.01 mmol) and acceptor **2c** (70 mg, 0.14 mmol) to afford following purification by silica gel column chromatography (Hexane: EtOAc, 5:1 to 2:1) **3c** as a colorless oil (72 mg, 72%). ^1^H NMR (500 MHz, CDCl~3~) δ 7 δ 7.98 (dd, *J* = 18.7, 7.7 Hz, 5H, Ar--H), 7.87 (d, *J* = 7.8 Hz, 2H, Ar--H), 7.55--7.52 (m, 2H, Ar--H), 7.39 (t, *J* = 7.7 Hz, 4H, Ar--H), 7.32--7.28 (m, 2H, Ar--H), 6.20--6.09 (m, 2H, H-2, H-2'), 6.04 (dd, *J* = 10.0, 3.0 Hz, 1H, H-3′), 5.72 (t, *J* = 9.8 Hz, 1H, H-4), 5.30--5.26 (m, 2H, H-1, H-3), 5.13 (d, *J* = 2.9 Hz, 1H, H-1'), 5.04 (dd, *J* = 5.5, 2.5 Hz, 1H, H-4'), 4.39 (ddd, *J* = 7.8, 5.4, 2.4 Hz, 1H, H-5′), 4.26 (dt, *J* = 10.4, 3.7 Hz, 1H, H-5), 4.16--3.99 (m, 3H, H-6a, H-6a', H-6b'), 3.74 (dd, *J* = 11.1, 3.0 Hz, 1H, H-6b), 3.50 (s, 3H, OCH~3~), 2.07 (s, 3H, COCH~3~), 1.86 (s, 3H, COCH~3~).^13^C NMR (126 MHz, CDCl~3~) δ 170.5 (*C*OCH~3~), 170.3 (*C*OCH~3~), 165.8 (*C*OPh), 165.8 (*C*OPh), 165.2 (*C*OPh), 133.5 (Ar--C), 133.4 (Ar--C), 133.1 (Ar--C) 130.1 (Ar--C), 129.9 (Ar--C), 129.8 (Ar--C), 129.2 (C-2'), 129.1 (Ar--C), 128.5 (Ar--C), 128.4 (Ar--C), 128.3 (Ar--C), 125.3, (C-3′) 97.1 (C-1), 93.9 (C-1′), 72.1(C-3), 70.6 (C-2), 69.4 (C-4), 68.3 (C-5), 66.6 (C-5′), 66.1 (C-6), 62.6 (2C- 4′, 6′), 55.7 (OCH~3~), 20.8 (CO*C*H~3~), 20.5 (CO*C*H~3~); ESI-HRMS for C~38~H~38~O~14~Na^+^ (MNa^+^) calculated: 741.2159; found: 741.2161

### Thiophenyl-6-*O*-(4,6-di-*O*-acetyl-2,3-dideoxy-α-[d]{.smallcaps}-*threo*-hex-2-enopyranosyl)-2,3,4-tri-*O-*benzoyl-α-[d]{.smallcaps}-glucopyranoside (**3d**) {#sec4.2.4}

Following the general glycosylation procedure, donor **1a** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.01 mmol) and acceptor **2d** (80 mg, 0.14 mmol) to afford following purification by column chromatography (Hexane:EtOAc, 5:1 to 1:1) **3d** as a colorless oil (85 mg, 72%). ^1^H NMR (500 MHz, CDCl~3~) δ 8.00--7.96 (m, 2H, Ar--H), 7.96--7.91 (m, 2H, Ar--H), 7.82--7.78 (m, 2H, Ar--H), 7.57--7.50 (m, 4H, Ar--H), 7.41 (m, 5H, Ar--H), 7.35--7.25 (m, 5H, Ar--H), 6.10 (ddd, *J* = 10.1, 5.5, 1.0 Hz, 1H, H-2'), 5.96 (dd, *J* = 10.0, 3.1 Hz, 1H, H-3′), 5.91 (t, *J* = 9.5 Hz, 1H, H-3), 5.63 (t, *J* = 9.7 Hz, 1H, H-4), 5.49 (t, *J* = 9.7 Hz, 1H, H-2), 5.12 (d, *J* = 3.1 Hz, 1H, H-1'), 5.08 (d, *J* = 10.0 Hz, 1H, H-1), 4.97 (dd, *J* = 5.5, 2.5 Hz, 1H, H-4'), 4.32 (ddd, *J* = 7.8, 5.4, 2.5 Hz, 1H, H-5′), 4.16--4.08 (m, 2H, H-6a′. H-6b′), 4.07--4.00 (m, 2H, H-5, H-6a), 3.83--3.77 (m, 1H, H-6b), 2.08 (s, 3H, COCH~3~), 1.93 (s, 3H, COCH~3~). ^13^C NMR (126 MHz, CDCl~3~) δ 170.5 (*C*OCH~3~), 170.3 (*C*OCH~3~), 165.8 (*C*OPh), 165.1 (*C*OPh), 165.0 (*C*OPh), 133.5 (Ar--C), 133.2 (Ar--C), 132.6 (Ar--C), 132.1 (Ar--C), 130.1 (C-3′), 129.9 (Ar--C), 129.8 (Ar--C), 129.7 (Ar--C), 129.2 (Ar--C), 128.9 (Ar--C), 128.9 (Ar--C), 128.8 (Ar--C), 128.5 (Ar--C), 128.4 (Ar--C), 128.3 (Ar--C), 128.2 (Ar--C), 125.3 (C-2'), 93.8 (C-1′), 85.9 (C-1), 77.2 (C-5), 74.3 (C-3), 70.5 (C-2), 69.5 (C-4) 66.7 (C-5′) 66.5 (C-6), 62.7 (C-6′), 62.6 (C-4′), 20.8 (CO*C*H~3~), 20.6 (CO*C*H~3~). ESI-HRMS for C~43~H~40~O~13~SNa^+^ (MNa^+^) calculated: 819.2087; found: 819.2103.

### 6-*O*-(4,6-di-*O*-acetyl-2,3-dideoxy-α-[d]{.smallcaps}-*threo*-hex-2-enopyranosyl)-1,2:4,5-di-*O*-isopropylidene-α-[d]{.smallcaps}-galacopyranoside (**3e**) {#sec4.2.5}

Following the general glycosylation procedure, donor **1a** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.01 mmol), and acceptor **2e** (36 mg, 0.14 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 7:1 to 4:1) **3e** as a colorless oil (49 mg, 75%). Spectroscopic data in agreement with literature.^[@ref15]^

### 2′-Propyn-1′-yl-4,6-di-*O*-acetyl-2,3-dideoxy-α/β-[d]{.smallcaps}-*threo*-hex-2-enopyranoside (**3f**) {#sec4.2.6}

Following the general glycosylation procedure, donor **1a** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.01 mmol) and acceptor **2f** (7.73 mg, 0.14 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 8:1 to 4:1) **3f** as a colorless oil (32 mg, 86%). Spectroscopic data in agreement with literature.^[@ref15]^

### Methyl 3-*O*-(4,6-di-*O*-acetyl-2,3-dideoxy-α-[d]{.smallcaps}-*threo*-hex-2-enopyranosyl)-4,6-*O*-benzylidene 2-*O-*benzyl-α-[d]{.smallcaps}-glucopyranoside (**3g**) {#sec4.2.7}

Following the general glycosylation procedure, donor **1a** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.01 mmol) and acceptor **2g** (51 mg, 0.14 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 5:1 to 3:1) **3g** as a colorless oil (55 mg, 68%)^1^H NMR (500 MHz, CDCl~3~) δ 7.42 (dd, *J* = 6.7, 2.8 Hz, 2H, Ar--H), 7.37--7.32 (m, 7H, Ar--H), 7.32--7.29 (m, 1H, Ar--H), 6.07 (dd, *J* = 3.2, 1.8 Hz, 2H, H-2′, H-3′), 5.54 (d, *J* = 2.0 Hz, 1H, H-1), 5.51 (s, 1H, H-PhCH), 5.00 (dd, *J* = 4.3, 2.7 Hz, 1H, H-4'), 4.81--4.69 (m, 1H, PhC*H*H), 4.57 (d, *J* = 12.2 Hz, 1H, PhC*H*H), 4.54 (d, *J* = 3.7 Hz, 1H, H-1), 4.51--4.46 (m, 1H, H-5′), 4.41 (t, *J* = 9.4 Hz, 1H, H-3), 4.25 (ddt, *J* = 13.2, 7.3, 3.3 Hz, 2H, H-6a′, H-6a), 4.05 (dd, *J* = 11.2, 7.2 Hz, 1H, H-6b'), 3.82 (td, *J* = 9.9, 4.8 Hz, 1H, H-5), 3.69 (t, *J* = 10.3 Hz, 1H, H-6b), 3.56 (t, *J* = 9.5 Hz, 1H, H-4), 3.46 (ddd, *J* = 13.1, 9.4, 3.6 Hz, 1H, H-2), 3.35 (s, 3H, OCH~3~), 2.06 (d, *J* = 6.1 Hz, 6H, 2 COCH~3~). ^13^C NMR (126 MHz, CDCl~3~) δ 170.8 (*C*OCH~3~), 170.4 (*C*OCH~3~), 138.2 (Ar--C), 137.2 (Ar--C), 130.8 (C-3′), 129.0 (Ar--C), 128.4 (Ar--C), 128.3 (Ar--C), 128.1 (Ar--C), 127.9 (Ar--C), 126.0 (Ar--C), 124.9 (C-2′), 101.4 (C-PhCH), 99.1 (C-1), 93.6 (C-1′), 82.8 (C-4), 78.1 (C-2), 73.4 (C-PhCH~2~), 73.1 (C-3), 69.1 (C-6), 66.4 (C-5′), 62.7 (C-4′), 62.2 (C-6′), 62.0 (C-5), 55.2 (OCH~3~), 20.8 (CO*C*H~3~), 20.70 (CO*C*H~3~). ESI-HRMS for C~31~H~36~O~11~Na^+^ (MNa^+^) calculated: 607.2155; found: 607.2155.

### 3-*O*-(4,6-di-*O*-acetyl-2,3-dideoxy-α-[d]{.smallcaps}-*threo*-hex-2- enopyranosyl)-l,2:5,6-di-*O*-isopropylidene-α-[d]{.smallcaps}-glucofuranose (**3h**) {#sec4.2.8}

Following the general glycosylation procedure, donor **1a** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.01 mmol), and acceptor **2h** (36 mg, 0.14 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 7:1 to 3:1) **3h** as a colorless oil (44 mg, 67%). ^1^H NMR (500 MHz, CDCl~3~) δ 6.16 (ddd, *J* = 10.0, 5.5, 1.1 Hz, 1H, H-2'), 6.09--5.99 (m, 1H, H-3′), 5.90 (d, *J* = 3.6 Hz, 1H, H-1), 5.39--5.34 (m, 1H, H-1′), 5.04 (dt, *J* = 5.5, 2.8 Hz, 1H, H-4′), 4.63 (d, *J* = 3.6 Hz, 1H, H-2), 4.41--4.28 (m, 3H, H-5′, H-3, H-6a′), 4.25--4.18 (m, 2H, H-4, H-6b′), 4.16--4.08 (m, 2H, H-5, H-6a), 3.99 (dd, *J* = 8.6, 5.1 Hz, 1H, H-6b), 2.13 (s, 3H), 2.10 (s, 3H), 1.52 (s, 3H), 1.42 (s, 3H), 1.33 (d, *J* = 4.1 Hz, 6H). ^13^C NMR (126 MHz, CDCl~3~) δ 170.8 (*C*OCH~3~), 170.3 (*C*OCH~3~), 130.0 (C-3′), 125.4 (C-2′), 112.0 (4°C), 109.17(4°C), 105.4 (C-1), 94.9 (C-1′), 84.3 (C-2), 81.3 (C-4), 80.77 (C-3), 72.7 (C-5), 67.8 (C-6), 67.2 (C-5′), 63.1 (C-6'), 62.8 (C-4′), 27.0 (C*C*H~3~), 26.9 (C*C*H~3~), 26.5 (C*C*H~3~), 25.4 (C*C*H~3~), 20.8 (CO*C*H~3~), 20.7 (CO*C*H~3~). ESI-HRMS for C~22~H~32~O~11~Na^+^ (MNa^+^) calculated: 495.1842; found: 495.1832.

### 4-Methoxyphenyl,4,6-di-*O*-acetyl-2,3-dideoxy-α-[d]{.smallcaps}-*threo*-hex-2-enopyranoside (**3i**) {#sec4.2.9}

Following the general glycosylation procedure, donor **1a** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.01 mmol) and acceptor **2i** (17 mg, 0.14 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 9:1 to 3:1) **3i** as a colorless oil (36 mg, 82%)^1^H NMR (500 MHz, CDCl~3~) δ 7.10--7.05 (m, 4H, Ar--H), 6.88--6.83 (m, 2H, Ar--H), 6.27 (ddd, *J* = 9.9, 5.4, 1.0 Hz, 1H, H-2), 6.21 (dd, *J* = 10.0, 3.0 Hz, 1H, H-3), 5.64 (dt, *J* = 3.0, 0.6 Hz, 1H, H-1), 5.13 (dd, *J* = 5.4, 2.5 Hz, 1H, H-4), 4.54 (ddd, *J* = 7.7, 5.3, 2.5 Hz, 1H, H-5), 4.29--4.23 (m, 2H, H-6a, H-6b), 3.80 (s, 3H, OCH~3~), 2.12 (s, COCH~3~), 1.98 (s, 3H, COCH~3~). ^13^C NMR (126 MHz, CDCl~3~) δ 170.6 (*C*OCH~3~), 170.4 (*C*OCH~3~), 155.2 (Ar--C), 151.0 (Ar--C), 129.9 (C-3), 125.9 (C-2), 118.8 (Ar--C), 114.5 (Ar--C), 93.7 (C-1), 67.5 (C-5), 62.6 (C-4), 62.5 (C-6), 55.7 (OCH~3~), 20.8 (CO*C*H~3~), 20.7 (CO*C*H~3~). ESI-HRMS for C~17~H~20~O~7~Na^+^ (MNa^+^) calculated: 359.1107; found: 359.1117.

### Cholesteryl-4,6-diacetyl-2,3-dideoxy-α-[d]{.smallcaps}-threo-2-enopyranoside (**3j**) {#sec4.2.10}

Following the general glycosylation procedure, donor **1a** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.01 mmol) and acceptor **2j** (53 mg, 0.14 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 4:1 to 2:1) **3j** as a colorless oil (65 mg, 79%) ^1^H NMR (500 MHz, Chloroform-*d*) δ 6.12 (dd, *J* = 10.0, 5.3 Hz, 1H, H-3), 6.03 (dd, *J* = 10.0, 3.0 Hz, 1H, H-2), 5.38 (dd, *J* = 4.9, 2.4 Hz, 1H, C = CH), 5.23 (d, *J* = 3.1 Hz, 1H, H-1), 5.04 (dd, *J* = 5.4, 2.5 Hz, 1H, H-4), 4.43 (ddd, *J* = 7.7, 5.6, 2.5 Hz, 1H, H-5), 4.27--4.20 (m, 2H, H-6a, H-6b), 3.59 (m, 1H), 2.44 (ddd, *J* = 13.4, 5.2, 2.1 Hz, 1H), 2.39--2.24 (m, 1H), 2.09 (d, *J* = 5.2 Hz, 6H, 2 COCH~3~), 2.05--1.95 (m, 3H), 1.93--1.79 (m, 3H), 1.63--1.05 (m, 16H), 1.02 (s, 5H), 0.93 (d, *J* = 6.5 Hz, 4H), 0.88 (dd, *J* = 6.6, 2.2 Hz, 8H), 0.69 (s, 3H). ^13^C NMR (126 MHz, CDCl~3~) δ 170.7 (*C*OCH~3~), 170.4 (*C*OCH~3~), 140.8 (C = CH), 131.2 (C-2), 125.0 (C-3), 121.8 (C = CH), 92.4 (C-1), 78.0, 66.7 (C-5), 63.0 (2C-6, 4)), 56.8 (CH), 56.2 (CH), 50.2 (CH), 42.3 (4 °C), 40.4 (CH~2~), 39.8 (CH~2~), 39.5 (CH~2~), 37.2 (4 °C), 36.7 (CH~2~), 36.2 (CH), 35.8, 31.9, 31.9, 28.2, 28.0, 24.3, 23.8, 22.8, 22.6, 21.1 (CO*C*H~3~), 20.8 (CO*C*H~3~), 19.3 (CH~3~), 18.7 (CH~3~), 11.9 (CH~3~). ESI-HRMS for C~37~H~58~O~6~Na^+^ (MNa^+^) calculated: 621.4131; found: 621.4126.

### *N*-Succinimido-4,6-diacetyl-2,3-dideoxy-α-[d]{.smallcaps}-threo-2-enopyranoside (**3k**) {#sec4.2.11}

Following the general glycosylation procedure, donor **1a** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.01 mmol) and acceptor **2k** (16 mg, 0.14 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 3:1 to 1:1) **3k** as a colorless oil (41 mg, 91%). ^1^H NMR (500 MHz, CDCl~3~) δ 6.36 (ddd, *J* = 10.0, 5.6, 1.2 Hz, 1H, H-3), 6.20 (ddd, *J* = 10.0, 3.1, 0.6 Hz, 1H, H-2), 5.64 (ddd, *J* = 3.2, 1.2, 0.6 Hz, 1H, H-1), 5.15 (ddd, *J* = 5.6, 2.7, 0.6 Hz, 1H, H-4), 4.81 (td, *J* = 6.3, 2.7 Hz, 1H, H-5), 4.33 (dd, *J* = 11.3, 6.2 Hz, 1H, H-6a), 4.07 (dd, *J* = 11.3, 6.5 Hz, 1H, H-6b), 2.75 (s, 4H, 2CH~2~), 2.08 (s, 3H, COCH~3~), 2.07 (s, 3H, COCH~3~). ^13^C NMR (126 MHz, CDCl~3~) δ 171.0 (2 NHS CO), 170.6 (*C*OCH~3~), 170.1 (*C*OCH~3~), 128.8 (C-3), 125.9 (C-2), 97.5 (C-1), 68.3 (C-5), 61.9 (C-4), 61.8 (C-6), 25.5 (2 CH~2~), 20.8 (CO*C*H~3~), 20.7 (CO*C*H~3~). ESI-HRMS for C~14~H~17~NO~8~Na^+^ (MNa^+^) calculated: 350.0852; found: 350.0862.

### 6-*O*-(4,6-di-*O*-acetyl-2,3-dideoxy-α-[d]{.smallcaps}-*erythro*-hex-2-enopyranosyl)-1,2:4,5-di-*O*-isopropylidene-α-[d]{.smallcaps}-galacopyranoside (**4b**) {#sec4.2.12}

Following the general glycosylation procedure, donor **1b** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.01 mmol) and acceptor **2e** (36 mg, 0.14 mmol) to afford following purification by column chromatography (Hexane:EtOAc, 8:1 to 4:1) **4b** as a yellow oil (56 mg, 86%). Spectroscopic data in agreement with literature.^[@cit9b]^

### 4-*O*-(acetyl)-2,3,6-trideoxy-α-[l]{.smallcaps}-hex-2-enopyranosyl-(1 → 6)-1,2;3,4-di-*O*-isopropylidene-α-[d]{.smallcaps}-galactopyranoside (**4c**) {#sec4.2.13}

Following the general glycosylation procedure, donor **1c** (50 mg, 0.12 mmol), B(C~6~F~5~)~3~ (6 mg 0.011 mmol), and acceptor **2e** (46 mg, 0.10 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 8:1 to 5:1) **4c** as a yellow oil (52 mg, 71%). ^1^H NMR (500 MHz, CDCl~3~) δ 6.14--5.95 (m, 2H, H-2′, H-3′), 5.53 (d, *J* = 5.0 Hz, 1H, H-1), 5.10 (d, *J* = 1.8 Hz, 1H, H--I′), 4.92 (dd, *J* = 4.4, 2.5 Hz, 1H, H-4'), 4.60 (dd, *J* = 7.9, 2.4 Hz, 1H, H-3), 4.31 (dd, *J* = 5.1, 2.4 Hz, 1H, H-2), 4.28--4.21 (m, 2H, H-5′, H-4), 3.99--3.91 (m, 2H, H-5, H-6a), 3.72--3.64 (m, 1H, H-6b), 2.10 (s, 3H, COCH~3~), 1.53 (s, 3H, C*C*H~3~), 1.45 (s, 3H, C*C*H~3~), 1.33 (s, 5H, C*C*H~3~), 1.22 (d, *J* = 6.6 Hz, 3H, C*C*H~3~). ^13^C NMR (126 MHz, CDCl~3~) δ 170.7 (*C*OCH~3~), 130.5 (C-3′), 125.8 (C-2′), 109.2 (*C*CH~3~), 108.5 (*C*CH~3~), 96.3 (C-1), 94.0 (C-1′), 71.1 (C-5′), 70.6 (C-3), 70.5 (C-2), 67.0 (C-5), 66.1 (C-6), 65.1 (C4′), 64.6 (C-4), 26.1 (C*C*H~3~), 26.0 (C*C*H~3~), 24.9 (C*C*H~3~), 24.5 (C*C*H~3~), 20.9 (CO*C*H~3~), 15.9 (C*C*H~3~). ESI-HRMS for C~20~H~30~O~9~Na^+^ (MNa^+^) calculated: 437.1788; found: 437.1788.

### 6-*O*-(*R*-2,3-dihydro-2H-pyran-4-yl acetate)-1,2:4,5-di-*O*-isopropylidene-α-[d]{.smallcaps}-galacopyranoside (**4d**) {#sec4.2.14}

Following the general glycosylation procedure, donor **1d** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (6 mg 0.011 mmol) and acceptor **2e** (36 mg, 0.14 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 10:1 to 6:1) **4d** as a colorless oil (56 mg, 75%). ^1^H NMR (400 MHz, CDCl~3~) δ 6.09--5.99 (m, 2H, H-2′, H-3′), 5.54 (d, *J* = 5.1 Hz, 1H, H-1), 5.09 (d, *J* = 2.3 Hz, 1H, H-1′), 4.95--4.91 (m, 1H, H-4′)), 4.59 (dd, *J* = 7.9, 2.4 Hz, 1H, H-3), 4.30 (dd, *J* = 5.1, 2.4 Hz, 1H, H-2), 4.23--4.15 (m, 2H, H-4, H-6a), 3.99 (ddd, *J* = 7.1, 4.8, 1.9 Hz, 1H, H-5), 3.90--3.72 (m, 3H, H-6b, H-5a′, H-5b′), 2.08 (s, 3H, COCH~3~), 1.52 (s, 3H, CCH~3~), 1.43 (s, 3H CCH~3~), 1.32 (s, 6H, 2 CCH~3~). ^13^C NMR (101 MHz, CDCl~3~) δ 170.6 (*C*OCH~3~), 130.9 (C-3′), 124.7 C-2′), 109.3 (*C*CH~3~), 108.5 (*C*CH~3~), 96.3 (C-1), 93.5 (C-1′), 71.2 (C-4′), 70.7 (C-3), 70.4 (C-2), 67.4 (C-5), 67.3 (C-5′), 63.4 (C-4), 61.4 (C-6), 26.0 (C*C*H~3~), 26.0 (C*C*H~3~), 24.9 (C*C*H~3~), 24.5 (C*C*H~3~), 21.1 (CO*C*H~3~).). ESI-HRMS for C~19~H~28~O~9~Na^+^ (MNa^+^) calculated: 423.1631; found: 423.1623.

### 4-*O*-(acetyl)-2,3,6-trideoxy-α-[l]{.smallcaps}-hex-2-enopyranosyl-(1 → 6)-1,2;3,4-di-*O*-isopropylidene-α-[d]{.smallcaps}-galactopyranoside (**4e**) {#sec4.2.15}

Following the general glycosylation procedure, donor **1e** (50 mg, 0.12 mmol), B(C~6~F~5~)~3~ (6 mg 0.011 mmol) and acceptor **2e** (46 mg, 0.10 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 15:1 to 8:1) **4e** as a yellow oil (48 mg, 65%). Spectroscopic data in agreement with literature.^[@cit9b]^

### 3-*N*-Boc-propyl acetyl-2,3,6-trideoxy-α-[l]{.smallcaps}-hex-2-enopyranosyl (**4f**) {#sec4.2.16}

Following the general glycosylation procedure, donor **1e** (50 mg, 0.12 mmol), B(C~6~F~5~)~3~ (6 mg 0.011 mmol), and acceptor **2l** (31 mg, 0.10 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 5:1 to 3:1) **4f** as a yellow oil (50 mg, 85%). ^1^H NMR (500 MHz, CDCl~3~) δ 1.24 (d, *J* = 6.6 Hz, 3H, CCH~3~), 1.45 (s, 9H, OC(CH~3~)~3~), 1.80 (dt, *J* = 11.6, 5.9 Hz, 2H, CH~2~), 2.12 (s, 3H, COCH~3~), 3.18--3.29 (m, 2H, NHCH~2~), 3.56 (dt, *J* = 9.9, 6.0 Hz, 1H, OCH*H*), 3.82--3.87 (m, 1H. OCH*H*), 4.23 (qd, *J* = 6.7, 2.3 Hz, 1H, H-5), 4.70 (s, 1H, NH), 4.93 (dd, *J* = 5.4, 2.5 Hz, 1H, H-4), 5.02 (d, *J* = 2.9 Hz, 1H, H-1), 6.02 (ddt, *J* = 9.9, 3.1, 0.7 Hz, 1H, H-2), 6.09 (ddd, *J* = 10.0, 5.4, 1.0 Hz, 1H, H-3). ^13^C NMR (126 MHz, CDCl~3~) δ 170.7 (*C*OCH~3~), 155.9 (NHCO), 130.3 (C-2), 125.9 (C-3), 94.3 (C-1), 69.5 (O*C*(CH~3~)~3~) 66.3 (OCH~2~), 65.0 (C-4), 64.7 (C-5), 38.2 (NHCH~2~), 29.9 (CH~2~), 28.4 (OC(*C*H~3~)~3~), 20.9(CO*C*H~3~), 16.1. ESI-HRMS for C~16~H~27~NO~6~Na^+^ (MNa^+^) calculated: 352.1736; found: 352.1748

### (3-*N*-Boc-propyl)-acetyl-2,3,6-trideoxy-α-[l]{.smallcaps}-hex-2-enopyranosyl (**5**) {#sec4.2.17}

To a stirring solution of glycoside **4f** (200 mg, 0.18 mmol) in 5 mL of methanol, 20 mol % K~2~CO~3~ (36 mg, 0.14 mmol) was added. The solution was stirred at RT until the reaction was determined to be complete by TLC. The reaction mixture was concentrated in vacuo and the dried residue diluted in CHCl~3~ (20 mL) and washed with water (20 mL), brine (20 mL), and dried over anhydrous MgSO~4~. The organic phase was concentrated in vacuo and purified by silica gel column chromatography (Hexane:EtOAc, 3:1 to 1:1) to afford **5** as a colorless oil (170 mg, 75%). ^1^H NMR (500 MHz, CDCl~3~) δ 1.30 (dd, *J* = 6.7, 2.3 Hz, 3H, CCH~3~), 1.44 (s, 9H, OC(CH~3~)~3~), 1.79 (p, *J* = 6.9 Hz, 2H, CH~2~), 3.24 (s, 2H, NHCH~2~), 3.51--3.63 (m, 2H, OCH*H*, H-4), 3.84 (dddd, *J* = 10.4, 9.3, 5.6, 2.8 Hz, 1H, OCH*H*), 4.11 (qd, *J* = 6.7, 3.2 Hz, 1H, H-5), 4.72 (s, 1H, NH), 4.95 (s, 1H, H-1), 5.84--5.92 (m, 1H, H-2), 6.15--6.22 (m, 1H, H-3). ^13^C NMR (126 MHz, CDCl~3~) δ 155.9 (NHCO), 130.3 (C-3), 128.1 (C-2), 94.6 (C-1), 79.1 (O*C*(CH~3~)~3~), 66.4 (C-5), 66.2 (OCH~2~), 63.9 (C-4), 38.2 (NHCH~2~), 29.9 (CH~2~), 28.4 (OC(*C*H~3~)~3~), 16.1 (C*C*H~3~). ESI-HRMS for C~14~H~25~NO~5~Na^+^ (MNa^+^) calculated: 310.1630; found: 310.1629.

### (3-*N*-Boc-propyl)-α-[l]{.smallcaps}-Rhodinoside (**6**) {#sec4.2.18}

To a stirring solution of glycoside **5** (100 mg 0.348 mmol) in 2 mL of a 1:6 mixture of ethyl acetate;toluene at RT, 5 mol % of Rh--Al~2~O~3~ (25 mg) was added. The reaction mixture was placed under a H~2~ atmosphere (balloon) and was stirred at RT for 5h. The reaction mixture was filtered through diatomaceous earth and the filtrate was concentrated under vacuum. The dry residue was purified by silica gel column chromatography (Hexane:EtOAc, 5:1 to 2:1) **6** as a colorless oil (77 mg, 76%). ^1^H NMR (500 MHz, CDCl~3~) δ 4.87 (s, 1H, NH), 4.73--4.77 (m, 1H, H-1), 3.90 (q, *J* = 6.7, 6.0 Hz, 1H, H-5), 3.70 (ddd, *J* = 9.9, 7.2, 5.1 Hz, 1H, OCH*H*), 3.55 (s, 1H, H-4), 3.39--3.48 (m, 1H, OCH*H*), 3.19 (dd, *J* = 26.9, 5.8 Hz, 2H, NHCH~2~), 2.08 (s, 1H, OH), 1.89--2.02 (m, 2H, H-2a, H-3a), 1.67--1.81 (m, 3H, H-3b, CH~2~), 1.48--1.55 (m, 1H, H-2b), 1.41 (s, 9H, OC(CH~3~)~3~), 1.15 (d, *J* = 6.6 Hz, 3H, CCH~3~),^13^C NMR (126 MHz, CDCl~3~) δ 155.9 (NHCO), 97.2 (C-1), 73.9 (O*C*(CH~3~)~3~), 67.2 (C-5), 66.2 (C-4), 65.4 (OCH~2~), 38.7 (NHCH~2~), 29.5 (CH~2~), 28.4 (OC(*C*H~3~)~3~), 25.7 (C-3), 23.4 (C-2), 17.1 (C*C*H~3~). ESI-HRMS for C~14~H~27~NO~5~Na^+^ (MNa^+^) calculated: 312.1787; found: 312.1781.

### (3-*N*-Boc-propyl)-α-[l]{.smallcaps}-Cineruloside (**7**) {#sec4.2.19}

To a stirring solution of **5** (100 mg 0.348 mmol) in 2 mL of a 1:6 mixture of ethyl acetate;toluene at RT, 5% Rh--Al~2~O~3~ (25 mg) was added. The reaction mixture was placed under a H~2~ atmosphere (balloon) and was stirred at room temperature for 5 h. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under vacuum. To the dried residue, Dess-Martin periodinane (221 mg 0.52 mmol) in 5 mL CH~2~Cl~2~ solvent were added and the reaction left to stir for another 5h at RT. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under vacuum. The dry residue was purified by silica gel column chromatography (Hexane:EtOAc, 4:1 to 2:1) **7** as a colorless oil (77 mg, 76%). ^1^H NMR (500 MHz, CDCl~3~) δ 4.97 (t, *J* = 4.7 Hz, 1H, H-1), 4.73 (s, 1H, NH), 4.24 (q, *J* = 6.7 Hz, 1H, H-5), 3.83 (ddd, *J* = 10.0, 6.8, 5.5 Hz, 1H, OCH*H*), 3.55 (ddd, *J* = 10.0, 6.5, 5.4 Hz, 1H, OCH*H*), 3.25 (q, *J* = 6.0 Hz, 2H, NHCH~2~), 2.53 (ddd, *J* = 16.1, 8.0, 5.7 Hz, 1H, H-3b), 2.44 (ddd, *J* = 16.1, 8.7, 5.8 Hz, 1H, H-3a), 2.25--2.32 (m, 1H, H-2a), 2.01 (dddd, *J* = 14.1, 8.3, 5.7, 4.3 Hz, 1H, H-2b), 1.75--1.85 (m, 2H, CH~2~), 1.44 (s, 9H, OC(*C*H~3~)~3~), 1.29 (d, *J* = 6.7 Hz, 3H, CCH~3~).^13^C NMR (126 MHz, CDCl~3~) δ 210.3 (C-4, C~2~CO), 155.9 (NHCO), 96.8 (C-1), 79.2 (OC(*C*H~3~)~3~), 71.0 (C-5), 65.8 (OCH~2~), 38.3 (NHCH~2~), 33.6 (C-3), 29.8 (CH~2~), 29.0 (CH~2~), 28.4 (OC(*C*H~3~)~3~), 14.9 (C*C*H~3~). ESI-HRMS for C~14~H~25~NO~5~Na^+^ (MNa^+^) calculated: 310.1630; found: 310.1630.

### (3-*N*-Boc-propyl)-α-[l]{.smallcaps}-Aculoside (**8**) {#sec4.2.20}

To a flask loaded with **5** (100 mg 0.18 mmol), Dess-Martin periodinane (221 mg 0.52 mmol) in 5 mL CH~2~Cl~2~ solvent was added and the reaction left to stir for 6 h at RT. The reaction mixture was then filtered through diatomaceous earth, and the filtrate was concentrated under vacuum. The dry residue was purified by silica gel column chromatography (Hexane:EtOAc, 5:1 to 3:1) **8** as a colorless oil (84 mg 86% yield). ^1^H NMR (500 MHz, CDCl~3~) δ 6.84 (dd, *J* = 10.2, 3.5 Hz, 1H, H-2), 6.09 (d, *J* = 10.4 Hz, 1H, H-3), 5.18 (d, *J* = 3.5 Hz, 1H, H-1), 4.67 (s, 1H, NH), 4.55 (q, *J* = 6.8 Hz, 1H, H-5), 3.92 (dt, *J* = 9.9, 6.0 Hz, 1H, OCH*H*), 3.64 (dt, *J* = 9.9, 6.0 Hz, 1H, OCH*H*), 3.21--3.31 (m, 2H, NHCH~2~), 1.83 (p, *J* = 6.6 Hz, 2H, CH~2~), 1.45 (s, 9H, OC(*C*H~3~)~3~), 1.40 (d, *J* = 6.8 Hz, 3H, CCH~3~),^13^C NMR (126 MHz, CDCl~3~) δ 196.9 (C-4 CO), 155.9 (NHCO), 143.3 (C-2), 127.3 (C-3), 93.3 (C-1), 70.4 (O*C*(CH~3~)~3~), 67.2 (C-5), 38.0 (CH~2~), 30.0 (CH~2~), 29.7 (CH~2~), 28.0, (OC(*C*H~3~)~3~), 15.3 (C*C*H~3~). ESI-HRMS for C~14~H~23~NO~5~Na^+^ (MNa^+^) calculated: 308.1474; found: 308.1461.

### Methyl-2,3,4-tri-*O*-benzyl-6-*O*-(2-deoxy-3,4,6-tri-*O*-benzyl-α-[d]{.smallcaps}-lyxo-hexapyranosyl)-α-[d]{.smallcaps}-glucopyranoside (**10a**) {#sec4.2.21}

Following the general glycosylation procedure. Donor **9a** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (3 mg 0.006 mmol), and acceptor **2a** (42 mg, 0.09 mmol) to afford following purification by column chromatography (Hexane:EtOAc, 6:1 to 3:1) **10a** as a colorless oil (82 mg, 88%). Spectroscopic data in agreement with literature.^[@cit9a]^

### Benzyl 2-deoxy-3,4,6-tri-*O*-benzyl-α-[d]{.smallcaps}-lyxo-hexapyranoside (**10b**) {#sec4.2.22}

Following the general glycosylation procedure. Donor **9a** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (3 mg 0.006 mmol) and acceptor **2b** (10 mg, 0.09 mmol) to afford following purification by column chromatography (Hexane:EtOAc, 20:1 to 10:1) **10b** as a colorless oil (46 mg, 94%). Spectroscopic data in agreement with literature.^[@cit9a]^

### 6-*O*-(3,4,6-tri-*O*-benzyl-α-[d]{.smallcaps}-lyxo-hexapyranosyl)-1,2,3,4-di-*O*-isopropylidene-α-[d]{.smallcaps}-galactopyranoside (**10e**) {#sec4.2.23}

Following the general glycosylation procedure. Donor **9a** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (3 mg 0.006 mmol), and acceptor **2e** (23 mg, 0.09 mmol) to afford following purification by column chromatography (Hexane:EtOAc, 6:1 to 4:1) **10e** as a colorless oil (50 mg, 84%). Spectroscopic data in agreement with literature.^[@ref4]^

### Methyl 3-*O*-benzyl-2-*O*-(2-deoxy-3,4,6-tri-*O*-benzyl-α-[d]{.smallcaps}-lyxo-hexapyranosyl)-4,6-*O*-benzylidene-α-[d]{.smallcaps}-glucopyranoside (**10g**) {#sec4.2.24}

Following the general glycosylation procedure. Donor **9a** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (3 mg 0.006 mmol), and acceptor **2e** (34 mg, 0.09 mmol) to afford following purification by column chromatography (Hexane:EtOAc, 6:1 to 4:1) **10g** as a colorless oil (45 mg, 62%). Spectroscopic data in agreement with literature.^[@cit9a]^

### 3-*O*-(2-deoxy-3,4,6-Tri-*O*-benzyl-α-[d]{.smallcaps}-lyxo-hexapyranoside)-1,2:5,6-di-*O*-isopropylidene-α-[d]{.smallcaps}-glucofuranoside (**10h**) {#sec4.2.25}

Following the general glycosylation procedure. Donor **9a** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (3 mg 0.006 mmol) and acceptor **2h** (23 mg, 0.09 mmol) to afford following purification by column chromatography (Hexane:EtOAc, 6:1 to 3:1) **10h** as a colorless oil (41 mg, 68%). Spectroscopic data in agreement with literature.^[@cit9d]^

### Methyl-2,3,4-tri-*O*-benzyl-6-*O*-(2-deoxy-3,4,6-Tri-*O*-*tert*-butyldimethylsilyl-α-[d]{.smallcaps}-lyxo-hexapyranosyl)-α-[d]{.smallcaps}-glucopyranoside (**11b**) {#sec4.2.26}

Following the general glycosylation procedure. Donor **9b** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (3 mg 0.006 mmol) and acceptor **2a** (36 mg, 0.08 mmol) to afford following purification by column chromatography (Hexane:EtOAc, 10:1 to 8:1) **11b** as a colorless oil (68 mg, 92%). Spectroscopic data in agreement with literature.^[@cit9a]^

### Methyl-2,3,4-tri-*O*-benzyl-6-*O*-(2-deoxy-3,4,6-tri-*O*-methoxymethyl ether-α-[d]{.smallcaps}-lyxo-hexapyranosyl)-α-[d]{.smallcaps}-glucopyranoside (**11c**) {#sec4.2.27}

Following the general glycosylation procedure, donor **9c** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (5 mg 0.009 mmol) and acceptor **2a** (63 mg, 0.11 mmol) to afford following purification by silkica gel column chromatography (Hexane:EtOAc, 7:1 to 5:1) **11c** as a colorless oil (71 mg, 71%). Spectroscopic data in agreement with literature.^[@cit9a]^

### Methyl-2,3,4-tri-*O*-benzyl-6-*O*-(2-deoxy-4,6-*O*-\[Bis(tert-butyl)silylene\]-3-*O*-methoxymethyl ether-α-[d]{.smallcaps}-lyxo-hexapyranosyl)-α-[d]{.smallcaps}-glucopyranoside (**11d**) {#sec4.2.28}

Following the general glycosylation procedure, donor **9d** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (4 mg 0.008 mmol) and acceptor **2a** (53 mg, 0.11 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 10:1 to 7:1) **11d** as a colorless oil (74 mg, 82%). 1H NMR (400 MHz, CDCl~3~) δ 7.31 (dddd, J = 20.0, 16.0, 8.5, 5.8 Hz, 15H, Ar--H), 5.02--4.93 (m, 3H, H-1′, PhC*HH*), 4.83--4.77 (m, 3H, PhC*HH*, OCH-*H*), 4.74--4.65 (m, 2H, PhCH*H*, OCH-*H*), 4.61 (d, *J* = 3.5 Hz, 1H, H-1), 4.55 (d, *J* = 11.4 Hz, 1H, PhCH*H*), 4.38 (d, *J* = 2.0 Hz, 1H, H-4′), 4.05--3.96 (m, 3H, H-3, H-6a′, H-6b′), 3.88 (ddd, *J* = 12.2, 4.4, 2.7 Hz, 1H, H-3′), 3.78 (m, 2H, H-5, H-6a), 3.63 (d, *J* = 9.6 Hz, 1H, H-6b), 3.54 (dd, *J* = 9.7, 3.6 Hz, 1H, H-2), 3.51--3.45 (m, 1H, H-4), 3.42 (d, *J* = 3.1 Hz, 4H, H-5′, CH~2~OCH~3~), 3.38 (s, 3H, OCH~3~), 2.18 (td, *J* = 12.4, 3.6 Hz, 1H, H-2a′), 1.82 (dd, *J* = 12.5, 4.7 Hz, 1H, H-2b′), 1.04 (s, 18H, 2C(CH~3~)~3~). ^13^C NMR (101 MHz, CDCl~3~) δ 138.6 (Ar--C), 138.3 (Ar--C), 138.1 (Ar--C), 128.5 (Ar--C), 128.4 (Ar--C), 127.9 (Ar--C), 127.7 (Ar--C), 127.2 (Ar--C), 98.2 (C-1′), 97.9 (C-1), 95.0 (OCH~2~--*C*H~3~), 82.2 (C-3), 80.1 (C-2), 78.1 (C-4), 75.8 (PhCH~2~), 74.8 (PhCH~2~), 73.3 (PhCH~2~), 72.1 (C-3′), 70.4 (C-4′), 69.7 (C-5), 67.56 (2C, C-6′, C-5′), 65.9 (C-6), 55.7 (O*C*H~2~CH~3~), 55.1 (OCH~3~), 30.1 (C-2′), 27.6 (C(*C*H~3~)~3~), 27.4 (C(*C*H~3~)~3~), 23.4 (*C*(CH~3~)~3~), 20.8 (*C*(CH~3~)~3~). ESI-HRMS for C~44~H~62~O~11~SiNa^+^ (MNa^+^) calculated: 817.3959; found: 817.3965.

### Methyl-2,3,4-tri-*O*-benzyl-6-*O*-(2-deoxy-3,4,6-tri-*O*-benzyl-α-[d]{.smallcaps}-lyxo-hexapyranosyl)-α-[d]{.smallcaps}-glucopyranoside (**12a**) and Methyl-6-*O*-(4,6-di-*O*-acetyl-2,3-dideoxy-α-[d]{.smallcaps}-ery*threo*-hex-2-enopyranosyl)-2,3,4-tri-*O-*benzyl-α-[d]{.smallcaps}-glucopyranoside(**12a′**) {#sec4.2.29}

Following the general glycosylation procedure. Donor **11a** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (3 mg 0.006 mmol) and acceptor **2a** (42 mg, 0.09 mmol) to afford following purification by column chromatography (Hexane:EtOAc, 6:1 to 3:1) **12a** as a colorless oil (44 mg, 54%) and **12a′** as a colorless oil (7 mg, 10%). Spectroscopic data in agreement with literature.^[@cit4c]^

### Methyl-2,3,4-tri-*O*-benzyl-6-*O*-(2-deoxy-3,4-*O*-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-6-*O*-benzyl-α-[d]{.smallcaps}-*erythro*-hexapyranosyl)-α-[d]{.smallcaps}-glucopyranoside (**12b**) {#sec4.2.30}

Following the general glycosylation procedure, donor **11b** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (3 mg 0.006 mmol), and acceptor **2a** (36 mg, 0.08 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 12:1 to 8:1) **12b** as a colorless oil (56 mg, 78%). Spectroscopic data in agreement with literature.^[@cit9a]^

### Methyl-2,3,4-tri-*O*-benzyl-6-*O*-(2-deoxy-3,4-*O*-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-6-*O*-triisopropylsilyl-α-[d]{.smallcaps}-*erythro*-hexapyranosyl)-α-[d]{.smallcaps}-glucopyranoside (**12c**) {#sec4.2.31}

Following the general glycosylation procedure, donor **11c** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (2 mg 0.005 mmol) and acceptor **2a** (32 mg, 0.07 mmol) to afford following purification by silica gel column chromatography (Hexane:EtOAc, 12:1 to 8:1) **12c** as a colorless oil (51 mg, 73%). Spectroscopic data in agreement with literature.^[@cit9a]^

### 6-*O*-(2-deoxy-3,4-*O*-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-6-*O*-triisopropylsilyl-α-[d]{.smallcaps}-erythro-hexapyranosyl)-1,2,3,4-di-*O*-isopropylidene-α-[d]{.smallcaps}-galactopyranoside (**13**) {#sec4.2.32}

Following the general glycosylation procedure, donor **11c** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (2 mg 0.005 mmol), and acceptor **2e** (18 mg, 0.07 mmol) to afford following purification by column chromatography (Hexane:EtOAc, 16:1 to 10:1) **13** as a colorless oil (48 mg, 86%). ^1^H NMR (400 MHz, CDCl~3~) δ 0.83--1.18 (m, 49H, 7× SiCH(CH~3~)~2~), 1.32 (s, 6H, 2 O~2~C*C*H~3~), 1.43 (s, 3H, O~2~C*C*H~3~), 1.51 (s, 3H, O~2~C*C*H~3~), 1.66 (ddd, *J* = 13.3, 11.4, 3.7 Hz, 1H, H-2a′), 2.10 (dd, *J* = 12.9, 5.3 Hz, 1H, H-2b′), 3.49 (dd, *J* = 9.4, 8.3 Hz, 1H, H-4′), 3.54--3.61 (m, 1H, H-5′), 3.65 (dd, *J* = 10.7, 6.2 Hz, 1H, H-6b′), 3.79 (ddd, *J* = 17.8, 10.7, 6.4 Hz, 2H, H-6b, H-6a′), 3.97 (td, *J* = 6.5, 1.6 Hz, 1H, H-5), 4.00--4.08 (m, 2H, H-6a, H-3′), 4.20 (dd, *J* = 7.9, 1.8 Hz, 1H, H-4), 4.30 (dd, *J* = 5.0, 2.4 Hz, 1H, H-2), 4.60 (dd, *J* = 7.9, 2.3 Hz, 1H, H-3), 4.95 (d, *J* = 3.1 Hz, 1H, H-1′), 5.51 (d, *J* = 5.0 Hz, 1H, H-1). ^13^C NMR (101 MHz, CDCl~3~) δ 109.2 (O~2~*C*CH~3~), 108.4 (O~2~*C*CH~3~), 96.3 (C-1), 96.0 (C-1′), 74.6 (C-4′), 73.4 (C-5′), 71.6 (C-3′), 71.1 (C-4), 70.7 (2C, C-2, C-3), 65.5 (C-5), 64.5 (C-6′), 63.3 (C-6), 38.0 (C-2′), 26.0 (O~2~C*C*H~3~), 25.9 (O~2~C*C*H~3~), 24.9 (O~2~C*C*H~3~), 24.4 (O~2~C*C*H~3~), 18.0, 17.9, 17.6, 17.4, 17.37, 17.3, 17.2 (Si(CH(*C*H~3~)~2~)), 13.0, 12.8, 12.4, 12.3, 12.0 (Si(*C*H(CH~3~)~2~)). ESI-HRMS for C~39~H~76~O~11~Si~3~Na^+^ (MNa^+^) calculated: 827.4593; found: 827.4586

### Methyl-3-*O*-benzyl-2-*O*-(2-deoxy-3,4-*O*-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-6-*O*-triisopropylsilyl-α-[d]{.smallcaps}-erythro-hexapyranosyl)-4,6-*O*-benzylidene-α-[d]{.smallcaps}-glucopyranoside (**14**) {#sec4.2.33}

Following the general glycosylation procedure, donor **11c** (50 mg, 0.10 mmol), B(C~6~F~5~)~3~ (2 mg 0.005 mmol), and acceptor **2g** (26 mg, 0.07 mmol) to afford following purification by column chromatography (Hexane:EtOAc, 10:1 to 5:1) **14** as a colorless oil (41 mg, 64%). Spectroscopic data in agreement with literature.^[@cit9a]^

### Methyl-2,3,4-tri-*O*-benzyl-6-*O*-(2-deoxy-3,4,6-tri-*O*-benzyl-(axial/equatorial)2-^2^H-α-[d]{.smallcaps}-lyxo-hexapyranosyl)-α-[d]{.smallcaps}-glucopyranoside (**16*a*/16b**) {#sec4.2.34}

Following the General Glycosylation Procedure, galactal **9** (50 mg, 0.120 mmol), B(C~6~F~5~)~3~ (3 mg 0.006 mmol), and acceptor **2a** (42 mg, 0.090 mmol). Following purification by silica gel column chromatography (8:1 to 4:1, Hexane:EtOAc) to afford glycoside **16a/16b** as an oil (70 mg, 88%).^[@cit9a]^

### Hexafluoroisopropayl-4,6-di-*O*-acetyl-2,3-dideoxy-α-[d]{.smallcaps}-threo-hex-2-enopyranoside (**18**) {#sec4.2.35}

Following the General Glycosylation Procedure, galactal **1a** (50 mg, 0.18 mmol), B(C~6~F~5~)~3~ (5 mg 0.009 mmol) acceptor **17** (42 mg, 0.090 mmol) at 45°C. Following purification by silica gel column chromatography (6:1 to 4:1, Hexane:EtOAc) product **18** was obtained as an oil (45 mg, 87%). ^1^H NMR (500 MHz, CDCl~3~) δ 6.29 (ddd, *J* = 10.0, 5.7, 1.2 Hz, 1H, H-3), 6.09 (dd, *J* = 10.0, 3.0 Hz, 1H, H-2), 5.34 (d, *J* = 2.6 Hz, 1H, H-1), 5.08 (dd, *J* = 5.7, 2.5 Hz, 1H, H-4), 4.63 (hept, *J* = 5.4 Hz, 1H, HC(CF~3~)~2~), 4.35 (ddd, *J* = 7.3, 4.6, 2.4 Hz, 1H, H-5), 4.30 (dd, *J* = 11.6, 4.6 Hz, 1H, H-6a), 4.18 (dd, *J* = 11.6, 7.5 Hz, 1H, H-6b), 2.09 (s, 3H, COCH~3~), 2.07 (s, 3H, COCH~3~). ^13^C NMR (126 MHz, CDCl~3~) δ 170.5 (*C*OCH~3~), 170.1 (*C*OCH~3~), 127.9(C-2), 126.9 (C-3), 122.9 (CF~3~), 122.2 (CF~3~), 94.8 (C-1), 71.6--71.1 (*C*(CF~3~)~2~), 68.1 (C-5), 62.4 (C-6), 62.1 (C-4), 20.7 (CO*C*H~3~), 20.5 (*C*O*C*H~3~). ^19^F NMR (470 MHz, CDCl~3~) δ −73.52 (m, CF~3~), −73.61 (m, CF~3~). ESI-HRMS for C~13~H~14~F~6~O~6~Na^+^ (MNa^+^) calculated: 403.0592; found: 403.0600.

### Hexafluoroisopropayl-2-deoxy-3,4,6-tri-*O*-benzyl-α-D-lyxo-hexapyranoside (**19**) {#sec4.2.36}

Following the General Glycosylation Procedure, galactal **9a** (50 mg, 0.120 mmol), B(C~6~F~5~)~3~ (3 mg 0.006 mmol) acceptor **17** (42 mg, 0.090 mmol) at RT. Following purification by silica gel column chromatography (12:1 to 8:1, Hexane:EtOAc) product **19** was obtained as an oil (48 mg, 92%). ^1^H NMR (500 MHz, CDCl~3~) δ 7.46--7.23 (m, 15H, Ar--H), 5.28 (d, *J* = 3.6 Hz, 1H, H-1), 4.97 (d, *J* = 11.5 Hz, 1H, PhC*H*H), 4.67--4.61 (m, 3H, PhC*HH*. PhC*H*H), 4.50 (q, *J* = 11.9 Hz, 3H, PhC*HH*, HC(CF~3~)~2~), 4.06--3.99 (m, 2H, H-4, H-5), 3.95 (ddd, *J* = 12.1, 4.6, 2.3 Hz, 1H, H-3), 3.63 (dd, *J* = 9.3, 7.0 Hz, 1H, H-6a), 3.58 (dd, *J* = 9.3, 5.9 Hz, 1H, H-6b), 2.37 (td, *J* = 12.7, 3.9 Hz, 1H, H-2a), 2.19 (dd, *J* = 13.2, 4.6 Hz, 1H, H-2b). ^13^C NMR (126 MHz, CDCl~3~) δ 138.6 (Ar--C), 138.1 (Ar--C), 138.0 (Ar--C), 128.5 (Ar--C), 128.4 (Ar--C), 128.3 (Ar--C), 128.2 (Ar--C), 127.7 (Ar--C), 127.7 (Ar--C), 127.6 (Ar--C), 127.6 (Ar--C), 127.4 (Ar--C), 122.4 (CF~3~). 120.2 (CF~3~), 100.0 (C-1), 74.4 (PhCH~2~), 73.8 (C-3), 73.4 (PhCH~2~), 72.5 (C-4), 71.5 (*C*(CF~3~)~2~) 71.4 (C-5), 70.7 (PhCH~2~), 68.8 (C-6), 30.2 (C-2). ^19^F NMR (470 MHz, CDCl~3~) −73.24 (m, CF~3~), −73.40 (m, CF~3~). ESI-HRMS for C~30~H~30~F~6~O~5~Na^+^ (MNa^+^) calculated: 607.1895; found:607.1903.

### Synthesis of Methyl-2,3,4-tri-*O*-benzyl-6-*O*-(2-deoxy-3,4,6-tri-*O*-benzyl-α/b-[d]{.smallcaps}-lyxohexapyranosyl)-α-[d]{.smallcaps}-glucopyranoside (**10a**) {#sec4.2.37}

The glycosyl donor **9a** (1 equiv) and acceptor **2a** (0.83 equiv) were weighed into a microwave vial and placed under vacuum for 1 h, after which time the microwave vial was filled with N2. A solution mixture containing (*R*)-3,3′-Bis\[3,5-bis(trifluoromethyl)phenyl\]-1,1′-binaphthyl-2,2′-diyl hydrogenphosphate (0.1 equiv) and thiourea (0.1 equiv) in anhydrous CH~3~CN (1 mL) was stirred for 30 min, before adding it to the microwave vial containing **1a** and **2a**.The reaction mixture was stirred at RT for 4 h and then was purified by silica gel column chromatography (Hexane:EtOAc, 7:1 to 4:1) affording disaccharide **3a** as a colorless oil (66 mg 70%, 4:1 α:β). The spectroscopic data was in agreement with previously reported data.^[@ref15]^

### In Situ Anomerization Test of **10a** in the Presence of **2a** {#sec4.2.38}

Disaccharide **10a** (4:1 α:β, 1 equiv), acceptor monosaccharide **2a** (1 equiv), and B(C~6~F~5~)~3~ (5 mol %) were weighed into an oven-dried microwave vial, sealed and placed under vacuum for 1 h. Then the vial was filled with N2 followed by the addition of ∼1.0 mL of anhydrous toluene. The solutions were stirred and heated at 50 °C for 2 h without observing any change in the anomeric ratio (4:1 α/β) as monitored by NMR of the crude mixture.
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